NCT04518462View on ClinicalTrials.gov

Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries

PHASE3CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

April 5, 2021

Study Completion Date

April 5, 2021

Conditions
Lower Extremity SurgeryBunionMetatarsophalangeal FushionMidfoot FusionHindfoot FushionTotal Ankle Arthroplasty
Interventions
DRUG

Exparel

EXPAREL (bupivacaine liposome injectable suspension)

DRUG

Bupivacaine Hydrochloride

0.25% bupivacaine

Trial Locations (5)

77401

HD Research, Corp, Bellaire

85053

Arizona Research Center, Phoenix

91105

Lotus Clinical Research, Pasadena

02114

Massachusetts General Hospital, Boston

02467

Brigham and Women's Hospital, Chestnut Hill

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY